Literature DB >> 21462435

[Efficacy and safety of the combined therapy with citicholine and actovegin in the acute period of ischemic stroke].

N A Shamalov, L V Stakhovskaia, I M Shetova, N M Efremova, K V Anisimov.   

Abstract

One hundred and four patients with acute carotid ischemic stroke were included in the study. Patients were divided into 4 groups. Patients of control group (group 1) were treated with equal basic and reperfusional therapy without any cytoprotectors. Patients of the 2nd group received citicholine in dose 1000 mg per day. Patients of the 3rd group were treated with 250 ml actovegin per day. The NIH stroke scale, the modified Rankin scale and the Barthel index were used to assess neurological status dynamics. The significant decrease of neurological deficit and improvement of functional recovery were seen in patients treated both with citicholine and actovegin (p < 0.005) to the 30th day compared to the control group. There was a trend towards the decrease of brain infarction volume within 5 days after stroke in patients of the 4th group. No side-effects of citicholine and actovegin were found.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21462435

Source DB:  PubMed          Journal:  Zh Nevrol Psikhiatr Im S S Korsakova        ISSN: 1997-7298


  3 in total

1.  Actovegin in the management of patients after ischemic stroke: A systematic review.

Authors:  Philip la Fleur; Ardak Baizhaxynova; Emily Reynen; David Kaunelis; Dinara Galiyeva
Journal:  PLoS One       Date:  2022-06-30       Impact factor: 3.752

2.  A Randomised, Double-Blind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design.

Authors:  Alla Guekht; Ingmar Skoog; Amos D Korczyn; Vladimir Zakharov; Martin Eeg; Ulf Vigonius
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2013-12-14

3.  ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment.

Authors:  Alla Guekht; Ingmar Skoog; Sally Edmundson; Vladimir Zakharov; Amos D Korczyn
Journal:  Stroke       Date:  2017-05       Impact factor: 7.914

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.